Mainz Biomed B.V. (MYNZ): Price and Financial Metrics
GET POWR RATINGS... FREE!
MYNZ Stock Summary
- MYNZ's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.45 -- higher than merely 5.03% of US-listed equities with positive expected earnings growth.
- MYNZ's went public 1.37 years ago, making it older than only 1.21% of listed US stocks we're tracking.
- MYNZ's price/sales ratio is 239.06; that's higher than the P/S ratio of 98.47% of US stocks.
- Stocks that are quantitatively similar to MYNZ, based on their financial statements, market capitalization, and price volatility, are AREB, SOPA, CKX, BTB, and TLS.
- To dig deeper into the stock's financial statements, go to MYNZ's page on browse-edgar?action=getcompany&CIK=0001874252.
MYNZ Valuation Summary
- MYNZ's price/earnings ratio is -4; this is 117.7% lower than that of the median Healthcare stock.
- MYNZ's EV/EBIT ratio has moved up 281.6 over the prior 17 months.
Below are key valuation metrics over time for MYNZ.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MYNZ | 2023-03-17 | 239.0 | 4.0 | -4.0 | -3.0 |
| MYNZ | 2023-03-16 | 239.0 | 4.0 | -4.0 | -3.0 |
| MYNZ | 2023-03-15 | 227.5 | 3.8 | -3.8 | -2.8 |
| MYNZ | 2023-03-14 | 232.7 | 3.9 | -3.9 | -2.8 |
| MYNZ | 2023-03-13 | 231.8 | 3.9 | -3.9 | -2.8 |
| MYNZ | 2023-03-10 | 239.8 | 4.0 | -4.0 | -3.0 |
MYNZ Stock Price Chart Interactive Chart >
MYNZ Price/Volume Stats
| Current price | $6.11 | 52-week high | $17.81 |
| Prev. close | $6.60 | 52-week low | $5.42 |
| Day low | $5.84 | Volume | 48,800 |
| Day high | $6.55 | Avg. volume | 31,945 |
| 50-day MA | $6.78 | Dividend yield | N/A |
| 200-day MA | $8.10 | Market Cap | 73.38M |
Mainz Biomed B.V. (MYNZ) Company Bio
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Latest MYNZ News From Around the Web
Below are the latest news stories about MAINZ BIOMED NV that investors may wish to consider to help them evaluate MYNZ as an investment opportunity.
Sidoti's Small-Cap Virtual March ConferenceSidoti & Company, LLC has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March 22-23, 2023. |
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in GermanyLabor Staber to actively market and sell ColoAlert to its physician and patient network.BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficac |
Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early DetectionSponsor of Gastro Update 2023, 2-day scientific and training events for gastroenterology professionals Patient Education Day in the City of Mainz, Germany, where the Company is headquartered Germany-based molecular diagnostic specialist to support local colorectal cancer communities BERKELEY, Calif. and MAINZ, Germany, March 08, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of |
Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023Mainz Biomed to host several events for patients and healthcare professionals in Germany to increase awareness about the importance of early detection of colorectal cancer.BERKELEY, Calif. and MAINZ, Germany, March 01, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, joins advocacy organizations around the world in recognizing Colorectal Cancer Awareness Month in March. |
Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ETVirtual Fireside Chat via Paltalk PlatformBERKELEY, Calif. and MAINZ, Germany, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that its Chief Financial Officer Bill Caragol will appear on ClearThink IR Virtual Live on Wednesday, March 1, 2023 at 12 noon ET. The ClearThink IR Virtual Live, powered by Paltalk, is hosting a different CEO every Wednesday at 12 noon ET for a “fireside chat” fol |
MYNZ Price Returns
| 1-mo | -12.10% |
| 3-mo | -19.29% |
| 6-mo | -23.14% |
| 1-year | -63.74% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -13.94% |
| 2022 | -31.67% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...